Health ❯ Healthcare

Side Effects

Medication Risks Medication Side Effects Gastrointestinal Issues Adverse Reactions Common Side Effects Drug Safety Drug Interactions Vaccine Reactions Drug Reactions Drug Side Effects Medication Safety Adverse Events Chemotherapy Hair Loss GLP-1 Medications Medication Interactions Vaccine Side Effects Vaccine Safety Digestive Issues Drug Tolerability Serious Side Effects Adverse Effects Pruritus Opioid Side Effects Epinephrine Medication Effects Vaccines Neuropsychiatric Effects Skin Reactions Emergency Contraceptive Pills Vision Loss Treatment Side Effects Medication Tolerability Medication Discontinuation Neuropathy Gut-related Issues Aspirin Side Effects Pancreatitis FluMist Weight Loss Vision Problems Clinical Trials Omeprazole Topical Treatments Nausea Treatment Efficacy Statin Side Effects Gastrointestinal Effects Taste Changes Amlodipine Side Effects Patient Experiences Gastrointestinal Symptoms Stomatitis Patient Care Impfreaktionen Reactogenicity Medication Adverse Effects Respiratory Issues Neurological Effects Nutritional Deficiencies Ocular Issues GLP-1 Drugs Skin Health Cardiac Complications Ibuprofen Less Serious Side Effects Gastrointestinal Disorders Clinical Trial Findings Indigestion Vaccination Side Effects Drug Efficacy Alopecia

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

Clinical trial data showing similar A1c control to daily basal insulin support a U.S. rollout of prefilled KwikPens in coming months.

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Study Finds Small Increased Hair‑Loss Risk with GLP‑1 Drugs

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

Wegovy Pill Approved, Private Sales Start in UK

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

Honey Energy Supplement Recalled After FDA Finds Undeclared ED Drug

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Conditional EU Approval for Anktiva in BCG-Unresponsive Bladder Cancer

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial